Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.
Rajji TK, Baksh SN, Shade DM, Ismail Z, Burhan AM, Okhravi HR, Padala PR, Rosenberg PB, Schneider LS, Porsteinsson AP, Lyketsos CG; S-CitAD Research Group.
Rajji TK, et al.
Nat Med. 2025 May;31(5):1586-1591. doi: 10.1038/s41591-025-03569-y. Epub 2025 Mar 25.
Nat Med. 2025.
PMID: 40133524
Free PMC article.
Clinical Trial.
In total, 173 participants were randomized (84 escitalopram versus 89 placebo; mean s.d. age = 78.4 8.7 years; 90 men (52.0%); 127 White (73.4%)). The unadjusted risk difference at 12 weeks was 0.08 (95% confidence interval: -0.21, 0.06). Drug-related QT interva …
In total, 173 participants were randomized (84 escitalopram versus 89 placebo; mean s.d. age = 78.4 8.7 years; 90 men (52.0%); 12 …